Ollin Biosciences reported positive topline results from its phase 1b JADE study, showing that OLN324, a next-generation VEGF/Ang2 bispecific antibody, demonstrated faster and greater anatomic improvements in diabetic macular edema (DME) compared with faricimab (Vabysmo; Genentech). The randomized, head-to-head trial enrolled more than 160 patients with DME or wet age-related macular degeneration (wAMD).

In DME patients treated with a 4 mg dose of OLN324, nearly 90% achieved retinal dryness at 12 weeks, defined as central subfield thickness (CST) below 325 µm, compared with 57% of patients receiving faricimab. Early improvements were also observed at week 1, with mean reductions in CST of 79 µm vs 45 µm. In wAMD, anatomic outcomes were similar across treatment groups, though OLN324 showed numerically higher vision gains at 12 weeks in both DME and wAMD cohorts. No intraocular inflammation was reported with OLN324, while a single case occurred with faricimab. Retinal vasculitis was not observed in any patient.

Ollin plans to advance OLN324 into global phase 3 trials for both DME and wAMD in 2026, the company said in a press release. The company plans to report full results of the JADE study at the Angiogenesis, Exudation, and Degeneration 2026 symposium in February.